GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1×1 meetings at the following investor conferences:
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
This press release was published by a CLEAR® Verified individual.
Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St.…
Strategic elevation signals bold expansion as Doceree redefines healthcare marketing with AI-powered precision and purposeSHORT…
Next-generation EMR platform recognized for helping specialty practices deliver efficient, personalized patient careSAN FRANCISCO, Feb.…
Agentic AI integrates EHR and RTLS data to automate equipment workflows and improve operational efficiency,…
PUNE, India, Feb. 4, 2026 /PRNewswire/ -- For nearly a decade, robotic surgery was sold as progress.…
Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked…